Lipomics develops tools for drug discovery and personalized medicine using proprietary technologies for lipid metabolite analysis and data interpretation. Lipomics generates a comprehensive understanding of lipid metabolism from plasma, serum or tissue samples by combining quantitative measurements of lipid metabolites with proprietary algorithms for mapping the lipomic profiles to biochemical pathways. In partnership with pharmaceutical, biotechnology and nutrition companies, Lipomics uses its technology to speed drug discovery processes, improveclinical trial stratification, reduce late-stage drug attrition, discover new biomarkers and develop early tests for monitoring drug response. After several University collaborations over the period of the firm's SBIR awards, the firm was acquired by Tethrys in 2008 and then, in 2012, was acquired by the biochemical profiling company Metabolon
